Gregory Zarbis-Papstoitsis

Dr. Greg Zarbis-Papastoitsis is the SVP of Process and Manufacturing at Compass Therapeutics. Compass engineers and manufactures antibody combinations utilizing a proprietary platform to treat cancer and other diseases. Compass successfully filed its first IND in February 2019 for the treatment of solid tumors. Previously he was the SVP of Process and Manufacturing Sciences at Eleven Biotherapeutics. His group developed and transferred processes for manufacturing an IL-1 inhibitor, which was in Phase 3 clinical studies for Dry Eye Disease and Allergic Conjunctivitis, and an anti-IL6 antibody (filled successfully an IND), for treating Macular Edema. Prior to Eleven he was the Senior Director of Downstream and Analytical Development at PERCIVIA, LLC, developing platform technologies for proteins produced with the PER.C6® human cell line. Previously he was Associate Director of Process and Analytical Development at Syntonix Pharmaceuticals, responsible for the early clinical development of a long lasting Factor IX (ALPROLIX®). Before Syntonix Dr. Zarbis-Papastoitsis worked on the commercial process of HUMIRA® (Abbott/Abbvie), and the purification development of IL2-Diptheria Toxin, ONTAK® (Seragen). He received a Ph.D. in Biology at Binghamton University followed by 3 years of post-doctoral studies at Boston University School of Medicine investigating proteases in Alzheimer disease.